Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Dec;38(6):660–673. doi: 10.1038/bjc.1978.271

The natural history of antitumour immunity in human breast cancer assayed by tube leucocyte adherence inhibition.

M Lopez, R O'Connor, J K MacFarlane, D M Thomson
PMCID: PMC2009831  PMID: 369585

Abstract

The specificity of the tube LAI in breast cancer was examined in a study with coded samples of PBL. In addition, 64 patients with breast cancer had their LAI reactivity monitored and correlated with their clinical status for up to 3 years after mastectomy. When patients were assayed by tube LAI, 83, 72, and 29% with Stage I, and II and III breast cancer respectively were positive. In Stage IV brest cancer, 88% of those with local recurrence and 15% of those with disseminated cancer were positive. By contrast, 3% of control subjects were LAI+. A select group of patients admitted to hospital with suspicious breast lumps that histopathologically proved to be benign breast disease (BBD) had a higher incidence of LAI+ (12%), whereas of outpatients with BBD only 2% were LAI+. Most breast cancer patients LAI reactivity became negative 2--4 months after mastectomy, even when some harboured micrometastases. LAI reactivity remained absent in those patients who remained clinically "cancer-free". In the follow-up patients, LAI activity returned about 4 months before local recurrence. LAI reactivity was observed in 7/8 patients in the coded study and 14/15 patients in the follow-up study preceding and/or at the time of local recurrence. A few patients (15%) progressed to widespread cancer without preceding positive LAI activity. The results suggest that tumour-specific immunity rapidly fades after surgery and may play no role in the rejection of micrometastases by 6 months after surgery. In addition, the present study has shown that the human hose manifests tumour-specific immunity when the cancer is small, and suggests that the early detection of human cancer would depend upon reliable methods to measure the tumour-specific immune response.

Full text

PDF
669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen V., Bjerrum O., Bendixen G., Schiodt T., Dissing I. Effect of autologous mammary tumour extracts on human leukocyte migration in vitro. Int J Cancer. 1970 May 15;5(3):357–363. doi: 10.1002/ijc.2910050308. [DOI] [PubMed] [Google Scholar]
  2. Armitstead P. R., Gowland G. The leucocyte adherence inhibtion test in cancer of the large bowel. Br J Cancer. 1975 Nov;32(5):568–573. doi: 10.1038/bjc.1975.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baldwin R. W. In vitro assays of cell-mediated immunity to human solid tumors: problems of quantitation, specificity, and interpretation. J Natl Cancer Inst. 1975 Oct;55(4):745–748. doi: 10.1093/jnci/55.4.745. [DOI] [PubMed] [Google Scholar]
  4. Black M. M., Zachrau R. E., Shore B., Leis H. P., Jr Biological considerations of tumor-specific and virus-associated antigens of human breast cancers. Cancer Res. 1976 Feb;36(2 Pt 2):769–774. [PubMed] [Google Scholar]
  5. Bull D. M., Leibach J. R., Williams M. A., Helms R. A. Immunity to colon cancer assessed by antigen-induced inhibition of mixed mononuclear cell migration. Science. 1973 Sep 7;181(4103):957–959. doi: 10.1126/science.181.4103.957. [DOI] [PubMed] [Google Scholar]
  6. Canevari S., Fossati G., Della Porta G., Balzarini G. P. Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the disease. Int J Cancer. 1975 Nov 15;16(5):722–729. doi: 10.1002/ijc.2910160504. [DOI] [PubMed] [Google Scholar]
  7. Deichman G. I., Kluchareva T. E. Loss of transplantation antigen in primary simian virus 40-induced tumors and their metastases. J Natl Cancer Inst. 1966 Apr;36(4):647–655. doi: 10.1093/jnci/36.4.647. [DOI] [PubMed] [Google Scholar]
  8. Elias E. G., Elias L. L., Didolkar M. S., Hebel J. R. Cellular immunity in patients with colorectal adenocarcinoma measured by autologous leukocyte migration inhibition. Cancer. 1977 Aug;40(2):687–692. doi: 10.1002/1097-0142(197708)40:2<687::aid-cncr2820400215>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  9. Evans R., Alexander P. Role of macrophages in tumour immunity. I. Co-operation between macrophages and lymphoid cells in syngeneic tumour immunity. Immunology. 1972 Oct;23(4):615–626. [PMC free article] [PubMed] [Google Scholar]
  10. Fenyö E. M., Klein E., Klein G., Swiech K. Selection of an immunoresistant Moloney lymphoma subline with decreased concentration of tumor-specific surface antigens. J Natl Cancer Inst. 1968 Jan;40(1):69–89. [PubMed] [Google Scholar]
  11. Flores M., Marti J. H., Grosser N., MacFarlane J. K., Thomson D. M. An overview: antitumor immunity in breast cancer assayed by tube leukocyte adherence inhibition. Cancer. 1977 Feb;39(2):494–505. doi: 10.1002/1097-0142(197702)39:2<494::aid-cncr2820390218>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  12. Foti A. G., Cooper J. F., Herschman H., Malvaez R. R. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med. 1977 Dec 22;297(25):1357–1361. doi: 10.1056/NEJM197712222972501. [DOI] [PubMed] [Google Scholar]
  13. Fujisawa T., Waldman S. R., Yonemoto R. H. Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients. Cancer. 1977 Feb;39(2):506–513. doi: 10.1002/1097-0142(197702)39:2<506::aid-cncr2820390219>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  14. Grosser N., Marti J. H., Proctor J. W., Thomson D. M. Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell. Int J Cancer. 1976 Jul 15;18(1):39–47. doi: 10.1002/ijc.2910180107. [DOI] [PubMed] [Google Scholar]
  15. Grosser N., Thompson D. M. Tube leukocyte (monocyte) adherence inhibition assay for the detection of anti-tumour immunity. III. "Blockade" of monocyte reactivity by excess free antigen and immune complexes in advanced cancer patients. Int J Cancer. 1976 Jul 15;18(1):58–66. doi: 10.1002/ijc.2910180109. [DOI] [PubMed] [Google Scholar]
  16. Grosser N., Thomson D. M. Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes. Cancer Res. 1975 Sep;35(9):2571–2579. [PubMed] [Google Scholar]
  17. Halliday W. J., Miller S. Leukocyte adherence inhibition: a simple test for cell-mediated tumour immunity and serum blocking factors. Int J Cancer. 1972 May 15;9(3):477–483. doi: 10.1002/ijc.2910090304. [DOI] [PubMed] [Google Scholar]
  18. Haywood G. R., McKhann C. F. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J Exp Med. 1971 Jun 1;133(6):1171–1187. doi: 10.1084/jem.133.6.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hellström I., Hellström K. E., Shantz G. Demonstration of tumor-associated immunity with a leukocyte adherence inhibition (LAI) assay. Int J Cancer. 1976 Sep 15;18(3):354–361. doi: 10.1002/ijc.2910180314. [DOI] [PubMed] [Google Scholar]
  20. Hellström I., Hellström K. E., van Belle G., Warner G. A. Leukocyte-mediated reactivity to human tumors as detected by the leukocyte adherence inhibition test. I. Demonstration of tumor type-specific reactions. Am J Clin Pathol. 1977 Nov;68(5 Suppl):706–714. [PubMed] [Google Scholar]
  21. Herberman R. B., Oldham R. K. Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J Natl Cancer Inst. 1975 Oct;55(4):749–753. doi: 10.1093/jnci/55.4.749. [DOI] [PubMed] [Google Scholar]
  22. Holt P. G., Roberts L. M., Fimmel P. J., Keast D. The L.A.I. microtest: a rapid and sensitive precedure for the demonstration of cell-mediated immunity in vitro. J Immunol Methods. 1975 Sep;8(3):277–288. doi: 10.1016/0022-1759(75)90122-2. [DOI] [PubMed] [Google Scholar]
  23. Holán V., Hasek M., Bubeník J., Chutná J. Antigen-mediated macrophage adherence inhibition. Cell Immunol. 1974 Jul;13(1):107–116. doi: 10.1016/0008-8749(74)90231-7. [DOI] [PubMed] [Google Scholar]
  24. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  25. Leveson S. H., Howell J. H., Holyoke E. D., Goldrosen M. H. Leukocyte adherence inhibition: an automated microassay demonstrating specific antigen recognition and blocking activity in two murine tumor systems. J Immunol Methods. 1977;17(1-2):153–162. doi: 10.1016/0022-1759(77)90086-2. [DOI] [PubMed] [Google Scholar]
  26. Lopez M. J., Thomson D. M. Isolation of breast cancer tumour antigen from serum and urine. Int J Cancer. 1977 Dec 15;20(6):834–848. doi: 10.1002/ijc.2910200604. [DOI] [PubMed] [Google Scholar]
  27. Maluish A., Halliday W. J. Cell-mediated immunity and specific serum factors in human cancer: the leukocyte adherence inhibition test. J Natl Cancer Inst. 1974 May;52(5):1415–1420. doi: 10.1093/jnci/52.5.1415. [DOI] [PubMed] [Google Scholar]
  28. Marti J. H., Grosser N., Thomson D. M. Tube leukocyte adherence inhibition assay for the detection of anti-tumour immunity. II. Monocyte reacts with tumour antigen via cytophilic anti-tumour antibody. Int J Cancer. 1976 Jul 15;18(1):48–57. doi: 10.1002/ijc.2910180108. [DOI] [PubMed] [Google Scholar]
  29. Marti J. H., Thomson D. M. Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition. Br J Cancer. 1976 Aug;34(2):116–133. doi: 10.1038/bjc.1976.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. O'Toole C., Unsgaard B., Almgård L. E., Johansson B. The cellular immune response to carcinoma of the urinary bladder: correlation to clinical stage and treatment. Br J Cancer Suppl. 1973 Aug;1:266–275. [PMC free article] [PubMed] [Google Scholar]
  31. Powell A. E., Sloss A. M., Smith R. N., Makley J. T., Hubay C. A. Specific responsiveness of leukocytes to soluble extracts of human tumors. Int J Cancer. 1975 Dec 15;16(6):905–913. doi: 10.1002/ijc.2910160604. [DOI] [PubMed] [Google Scholar]
  32. Rieche K., Arndt A., Pasternak G. Cellular immunity in mammary cancer patients as measured by the leukocyte migration test (LMT). A follow-up study. Int J Cancer. 1976 Feb 15;17(2):212–218. doi: 10.1002/ijc.2910170210. [DOI] [PubMed] [Google Scholar]
  33. Rutherford J. C., Walters B. A., Cavaye G., Halliday W. J. A modified leukocyte adherence inhibition test in the laboratory investigation of gastrointestinal cancer. Int J Cancer. 1977 Jan;19(1):43–48. doi: 10.1002/ijc.2910190107. [DOI] [PubMed] [Google Scholar]
  34. Thomson D. M., Gold P., Freedman S. O., Shuster J. The isolation and characterization of tumor-specific antigens of rodent and human tumors. Cancer Res. 1976 Sep;36(9 Pt 2):3518–3525. [PubMed] [Google Scholar]
  35. Thomson D. M., Krupey J., Freedman S. O., Gold P. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A. 1969 Sep;64(1):161–167. doi: 10.1073/pnas.64.1.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Thomson D. M. Soluble tumour-specific antigen and its relationship to tumour growth. Int J Cancer. 1975 Jun 15;15(6):1016–1029. doi: 10.1002/ijc.2910150619. [DOI] [PubMed] [Google Scholar]
  37. Unsgaard B., O'Toole C. The influence of tumour burden and therapy on cellular cytotoxicity responses in patients with ocular and skin melanoma. Br J Cancer. 1975 Mar;31(3):301–316. doi: 10.1038/bjc.1975.65. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES